Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma

Journal of Gastrointestinal Cancer

Volumn 43, Issue 3, 2012, Pages 505-507

  Chang, Yongen ^a   Mbeo, Gilbert ^a   Littman, Susan J ^b  

^a AtlantiCare   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chemotherapy; Leukoencephalopathy; RPLS

Indexed keywords

BEVACIZUMAB; ETIRACETAM; GEMCITABINE; GEMOX; HYDROCHLOROTHIAZIDE; LABETALOL; LISINOPRIL; LORAZEPAM; OXALIPLATIN; PHENOBARBITAL; PHENYTOIN; UNCLASSIFIED DRUG;

ADULT; AGITATION; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CONFUSION; DRUG INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FATALITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; TONIC CLONIC SEIZURE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; FEMALE; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PROGNOSIS; SEIZURES;

EID: 84866369771     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-011-9279-8     Document Type: Article

References (22)

1. Levy CF, Oo KZ, Fireman F, et al. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer. 2009;52(5):669-71.
2. Hinchey JA. Reversible posterior leukoencephalopathy syndrome: what have we learned in the last 10 years? Arch Neurol. 2008;65(2):175-6.
3. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500.
4. Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet. 1994;344(8921):519-21.
5. Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep. 2008;10(1):86-91.
6. Marinella MA, Markert RJ. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J. 2009;39(12):826-34.
7. El Maalouf G, Mitry E, Lacout A, et al. Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol. 2008;255(2):295-6.
8. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63(10):1475-8.
9. Peter S, Hausmann N, Schuster A, et al. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab. Clin Experiment Ophthalmol. 2008;36(1):94-6.
10. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354(9):980-2. discussion 980-982.
11. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354(9):980-2. discussion 980-982.
12. Koopman M, Muller EW, Punt CJ. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case. Dis Colon Rectum. 2008;51(9):1425-6.
13. Guiu S, Taillibert S, Chinot O, et al. Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris). 2008;164(6-7):588-94.
14. Lievre A, Samalin E, Mitry E, et al. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer. 2009;9:347.
15. Bhatt A, Farooq MU, Majid A, et al. Chemotherapy-related posterior reversible leukoencephalopathy syndrome. Nat Clin Pract Neurol. 2009;5(3):163-9.
16. Maeda T, Kikuchi E, Matsumoto K, et al. Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient. Int J Clin Oncol. 2010;15(5):508-11.
17. Connolly RM, Doherty CP, Beddy P, et al. Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer. 2007;56(3):459-63.
18. Rangi PS, Partridge WJ, Newlands ES, et al. Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia. Neuroradiology. 2005;47(8):586-90.
19. Russell MT, Nassif AS, Cacayorin ED, et al. Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging. 2001;19(1):129-32.
20. Vieillot S, Pouessel D, de Champfleur NM, et al. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol. 2007;18(3):608-9.
21. Rajasekhar A, George Jr TJ. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist. 2007;12(11):1332-5.
22. Pinedo DM, Shah-Khan F, Shah PC. Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin. J Clin Oncol. 2007;25(33):5320-1.